Is Xylazine legal in New Zealand?
- Legal status
- Not a controlled drug on the text cited, and the absence was tested rather than assumed. Xylazine, a veterinary alpha-2 adrenergic sedative, has no exact entry in Schedules 1 to 3 of the Misuse of Drugs Act 1975, and the closed schedules were read together with the open section 2 analogue limb, whose definition excludes substances that are approved medicines or that lack substantial structural similarity to a controlled drug. That is why this is recorded as a positive closed-list absence and not as an unresolved question. It is reported as an adulterant of opioid powders whose named opioids, such as fentanyl and heroin, have their own rows here and are controlled, so a mixture can be controlled through a constituent this row does not reach. One route stays open: sale of an unapproved psychoactive product can engage the Psychoactive Substances Act 2013 even where no controlled drug classification attaches. The consolidation read was the one current at 20 September 2026, with the Order of 2025 commenced on 27 November 2025 as the latest instrument actually in force.
- Consequences if caught
- Capital exposure: none. New Zealand has no death penalty. No Misuse of Drugs Act ceiling attaches to xylazine either, because it is not established as a controlled drug on the cited text, so neither the section 6 dealing maximum nor the section 7 possession maximum has anything to fasten on. The exposure that does exist sits in the Psychoactive Substances Act 2013, on the route for unlawful sale of an unapproved psychoactive product, whose penalties are statutory and non-capital. That route reaches supply rather than a person carrying the substance. A powder containing it will usually also contain a named opioid, and the opioid rows carry the ceiling a seizure actually attracts.
- If prescribed or medical
- Not established for a traveller. This dossier carries no country-level rule for entering New Zealand with a prescribed medicine: it records that medicines status has to be checked alongside the analogue exclusions and the Psychoactive Substances Act 2013 route, and that a court-grade conclusion can turn on the medicine exclusions, but it states no declaration requirement, no permit, no quantity allowance and no carry limit at the border, and none was researched for this cell. What is established is the placement a traveller would be read against: xylazine is not established as a controlled drug on the text cited, so the Misuse of Drugs Act placement is a negative one and neither section 6 nor section 7 attaches to it. It is a veterinary product rather than a human medicine, so no human prescribing route is in view at all. Do not read that placement as a ruling on a lawfully prescribed and lawfully carried supply, which is a different question this cell does not answer. Settle the border question with the Ministry of Health, whose classification order implementation page this dossier cites, and with the New Zealand border authority, before travelling.
- Documentation
- Carry the Misuse of Drugs Act 1975 consolidation current at 20 September 2026 and the Psychoactive Substances Act 2013 together, because the finding for xylazine needs both: the first for the negative and the second for the route that remains. Read the opioid rows in this table for any mixture containing xylazine, because this row answers only the xylazine constituent. Carry the reasoning and not only the result, because a negative is worth no more than the limb it was tested against, and here that limb is the section 2 exclusion for approved medicines and for substances lacking substantial structural similarity. Carry the classification chain this finding was read against as well: the 2022 and 2025 Classification and Presumption of Supply Orders with their commencement orders, the 2024 pseudoephedrine amendment, and the 2026 Order, which was made but is not treated as law in this dossier because its own section 2 leaves commencement to the Governor-General and no commencement instrument was located by the horizon. Carry the date as well, 20 September 2026, because in New Zealand a classification order can move a substance between classes without a word of the Act changing.
- mpi.govt.nz
- The power that moves this list is section 4 of the Misuse of Drugs Act 1975, under which the Governor General by Order in Council amends Schedules 1 to 3 subject to approval and commencement machinery. As those schedules stand after the Misuse of Drugs (Classification and Presumption of Supply) Order 2025, effective 27 November 2025, which this project's New Zealand substance dossier checked on 20 September 2026 records as the latest commenced classification instrument located, a 2026 Order was made and no commencement instrument for it was located. That does not rule out a later amendment made or commenced since.
Want to know if New Zealand changes its law on Xylazine?
Drug-law changes, court decisions and research, once a month.
Free. We email you once to confirm. Unsubscribe with one click.
Court records
We have not yet assessed whether court records are publicly available for this jurisdiction.
Xylazine in related jurisdictions
Other substances confirmed in New Zealand
Same substance, other countries
Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with New Zealand’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
